Cargando…

Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals

Alzheimer’s disease biomarkers are primarily evaluated through MRI, PET and CSF methods in order to diagnose and monitor disease. Recently, advances in the assessment of blood-based biomarkers have shown promise for simple, inexpensive, accessible and minimally invasive tools with diagnostic and pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lussier, Firoza Z, Benedet, Andréa L, Therriault, Joseph, Pascoal, Tharick A, Tissot, Cécile, Chamoun, Mira, Mathotaarachchi, Sulantha, Savard, Melissa, Ashton, Nicholas J, Karikari, Thomas K, Rodriguez, Juan Lantero, Snellman, Anniina, Bezgin, Gleb, Kang, Min Su, Fernandez Arias, Jaime, Wang, Yi-Ting, Gauthier, Serge, Zetterberg, Henrik, Blennow, Kaj, Rosa-Neto, Pedro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088291/ https://www.ncbi.nlm.nih.gov/pubmed/33959711 http://dx.doi.org/10.1093/braincomms/fcab073

Ejemplares similares

Association of plasma P-tau181 with memory decline in non-demented adults
por: Therriault, Joseph, et al.
Publicado: (2021)

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET
por: Tissot, Cécile, et al.
Publicado: (2022)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Biomarker modeling of Alzheimer’s disease using PET-based Braak staging
por: Therriault, Joseph, et al.
Publicado: (2022)

Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment
por: Pascoal, Tharick A., et al.
Publicado: (2020)

Amyloid‐dependent and amyloid‐independent effects of Tau in individuals without dementia
por: Therriault, Joseph, et al.
Publicado: (2021)

Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals
por: Benedet, Andréa L., et al.
Publicado: (2019)

APOEε4 potentiates the relationship between amyloid-β and tau pathologies
por: Therriault, Joseph, et al.
Publicado: (2020)

CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
por: Simrén, Joel, et al.
Publicado: (2022)

Interactive rather than independent effect of APOE and sex potentiates tau deposition in women
por: Wang, Yi-Ting T, et al.
Publicado: (2021)

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
por: Moscoso, Alexis, et al.
Publicado: (2020)

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease
por: Moscoso, Alexis, et al.
Publicado: (2021)

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE ε4, and Cognitive Impairment
por: Therriault, Joseph, et al.
Publicado: (2021)

Mild behavioral impairment is associated with β‐amyloid but not tau or neurodegeneration in cognitively intact elderly individuals
por: Lussier, Firoza Z., et al.
Publicado: (2020)

Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s disease
por: Kang, Min Su, et al.
Publicado: (2020)

Verbal memory formation across PET-based Braak stages of tau accumulation in Alzheimer’s disease
por: Fernández Arias, Jaime, et al.
Publicado: (2023)

Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative
por: Zettergren, Anna, et al.
Publicado: (2021)

Topographic Distribution of Amyloid-β, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease
por: Therriault, Joseph, et al.
Publicado: (2021)

Impact of long- and short-range fibre depletion on the cognitive deficits of fronto-temporal dementia
por: Savard, Melissa, et al.
Publicado: (2022)

14-3-3 [Formula: see text] -reported early synaptic injury in Alzheimer’s disease is independently mediated by sTREM2
por: Woo, Marcel S., et al.
Publicado: (2023)

Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy
por: Grothe, Michel J., et al.
Publicado: (2021)

Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer's disease
por: Pascoal, Tharick A., et al.
Publicado: (2023)

Medial temporal tau predicts memory decline in cognitively unimpaired elderly
por: Kwan, Angela T H, et al.
Publicado: (2022)

Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease
por: Ferrari-Souza, João Pedro, et al.
Publicado: (2022)

Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies
por: Montoliu-Gaya, Laia, et al.
Publicado: (2023)

In vivo quantification of neurofibrillary tangles with [(18)F]MK-6240
por: Pascoal, Tharick A., et al.
Publicado: (2018)

Blood biomarkers and neurodegeneration in individuals exposed to repetitive head impacts
por: Bernick, Charles, et al.
Publicado: (2023)

Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET
por: Therriault, Joseph, et al.
Publicado: (2023)

Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials
por: Ferreira, Pamela C.L., et al.
Publicado: (2023)

Effects of pre‐analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography
por: Therriault, Joseph, et al.
Publicado: (2022)

Anosognosia predicts default mode network hypometabolism and clinical progression to dementia
por: Therriault, Joseph, et al.
Publicado: (2018)

Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [(18)F]THK5351 uptake in progressive supranuclear palsy
por: Ng, Kok Pin, et al.
Publicado: (2019)

Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer’s disease
por: Ng, Kok Pin, et al.
Publicado: (2021)

Bayesian workflow for the investigation of hierarchical classification models from tau-PET and structural MRI data across the Alzheimer’s disease spectrum
por: Belasso, Clyde J., et al.
Publicado: (2023)

APOEε4 associates with microglial activation independently of Aβ plaques and tau tangles
por: Ferrari-Souza, João Pedro, et al.
Publicado: (2023)

N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases
por: Snellman, Anniina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2nr91cldvhqnbrd9aicpqi97a2